Tikomed: TikoMed's ILB activates the body's natural repair s

VIKEN, Sweden, Aug. 3, 2022 /PRNewswire/ -- A new study with TikoMed's lead drug candidate, ILB, addressing underlying causes of neurodegeneration in acute and chronic diseases, was published

Related Keywords

Sweden , Richard Hayhurst , Ola Bjorkman , Anders Kristensson , Kostenloser Wertpapierhandel , Ann Logan , Giuseppe Lazzarino , Department Of Biomedical , University Of Catania , University Of Warwick , International Journal Of Molecular Sciences , Biotechnological Sciences , International Journal , Molecular Sciences , Professor Giuseppe , Principal Investigator , Scientific Director , Axolotl Consulting , Regenerative Medicine , Glasgow Coma Scale , Amyothrophic Lateral Sclerosis , Traumatic Brain Injury , Low Molecular Weight Dextran Sulphate , Restores Glutamate Homeostasis , Amino Acid Metabolism , Neurocognitive Functions , Rat Model , Severe Traumatic Brain , Neurosurg Sci , Tikomed , Eactivates , Body , Natural , Repair , Signals , Restore , Oglutamate , Homeostasis , Amino , Acid , Metabolism , Neurocognitive , Functions , Model , Evere , Traumatic , Rain , Injury ,